According to the Centers for Disease Control and Prevention (CDC), just over 40% of America's adult population qualifies as obese.

In an effort to confront that problem, President Donald Trump has officially announced that the price of anti-obesity drugs will be dropping. 

Substantial cost reductions coming

As Breitbart reported, that announcement came in the form of a fact sheet that the White House made public on Thursday.

.@POTUS: "Medicare and Medicaid will finally cover the cost of these [GLP-1] weight loss drugs for millions of patients... co-pays for Medicare patients will be as low as $50... you're talking about from $1,350 to $50!"

"This is tremendous news for the American seniors." pic.twitter.com/4EOdpWOm4m

— Rapid Response 47 (@RapidResponse47) November 6, 2025

It detailed how the Trump administration has reached a Most Favored Nation (MFN) pricing deal with pharmaceutical companies Eli Lilly & Company and Novo Nordisk.

Wegovy and Ozempic are produced by Novo Nordisk, and their monthly costs will drop to $350 from the current rates of $1,350 and $1,000 per month, respectively.

Online savings available

Meanwhile, Eli Lilly & Company’s Zepbound and Orforglipron are both expected to drop from $1,068 a month in price to just $346.

Those savings can be had when patients purchase their medication through TrumpRX, a website that is scheduled to be up and running by January.

"In the event that the FDA later approves the Wegovy pill, or certain similar ‘GLP-1’ drugs in each company’s pipeline intended to be taken orally rather than as a shot, the initial dose of those drugs will be priced at $150 per month through TrumpRx," the fact sheet stressed.

It went on to explain that "[t]he historic reduction in prices negotiated by President Trump will enable Medicare and Medicaid to cover obesity drugs for adults at a dramatically lower cost to taxpayers than that proposed by the Biden Administration."

The document further noted how the "Medicare prices of Ozempic, Wegovy, Mounjaro, and Zepbound will be $245" while "Medicare beneficiaries will pay a co-pay of just $50 per month."

Price reductions for diabetes, migraine drugs

In addition to having good news for obesity sufferers, the fact sheet also touted impending relief for those who struggle with diabetes and migraines.

Eli Lilly is set to offer migraine treatment Emgality at $299 per pen and diabetes medication Trulicity at $389 per month.

What's more, Novo Nordisk "will provide widely-used insulin products, including NovoLog and Tresiba, at $35 per month of supply."